Global Fabry Disease Therapeutic 麻豆原创 Research Report 2023

Publication ID:

PB510235009

Publication Date:

October 31, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Fabry Disease Therapeutic market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Fabry Disease Therapeutic market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Amicus therapeutics
Takeda
Genzyme-Sanofi
Protalix
Sanofi-Aventis LLC
Novartis Pharmaceuticals
Pfizer
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Amgen Inc.
Teva pharmaceutical Industries Ltd.
Merc & Co.
AbbVie Inc.
Takeda Pharmaceutical Co. Ltd.
Green Cross Corp.
Segment by Type
Enzyme Replacement Therapy
Alternative therapies
Segment by Application
Hospitals
Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Fabry Disease Therapeutic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Fabry Disease Therapeutic 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Enzyme Replacement Therapy
1.2.3 Alternative therapies
1.3 麻豆原创 by Application
1.3.1 Global Fabry Disease Therapeutic 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Fabry Disease Therapeutic 麻豆原创 Perspective (2018-2029)
2.2 Fabry Disease Therapeutic Growth Trends by Region
2.2.1 Global Fabry Disease Therapeutic 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Fabry Disease Therapeutic Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Fabry Disease Therapeutic Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Fabry Disease Therapeutic 麻豆原创 Dynamics
2.3.1 Fabry Disease Therapeutic Industry Trends
2.3.2 Fabry Disease Therapeutic 麻豆原创 Drivers
2.3.3 Fabry Disease Therapeutic 麻豆原创 Challenges
2.3.4 Fabry Disease Therapeutic 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Fabry Disease Therapeutic Players by Revenue
3.1.1 Global Top Fabry Disease Therapeutic Players by Revenue (2018-2023)
3.1.2 Global Fabry Disease Therapeutic Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Fabry Disease Therapeutic 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Fabry Disease Therapeutic Revenue
3.4 Global Fabry Disease Therapeutic 麻豆原创 Concentration Ratio
3.4.1 Global Fabry Disease Therapeutic 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Fabry Disease Therapeutic Revenue in 2022
3.5 Fabry Disease Therapeutic Key Players Head office and Area Served
3.6 Key Players Fabry Disease Therapeutic Product Solution and Service
3.7 Date of Enter into Fabry Disease Therapeutic 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Fabry Disease Therapeutic Breakdown Data by Type
4.1 Global Fabry Disease Therapeutic Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Fabry Disease Therapeutic Forecasted 麻豆原创 Size by Type (2024-2029)
5 Fabry Disease Therapeutic Breakdown Data by Application
5.1 Global Fabry Disease Therapeutic Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Fabry Disease Therapeutic Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Fabry Disease Therapeutic 麻豆原创 Size (2018-2029)
6.2 North America Fabry Disease Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Fabry Disease Therapeutic 麻豆原创 Size by Country (2018-2023)
6.4 North America Fabry Disease Therapeutic 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Fabry Disease Therapeutic 麻豆原创 Size (2018-2029)
7.2 Europe Fabry Disease Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Fabry Disease Therapeutic 麻豆原创 Size by Country (2018-2023)
7.4 Europe Fabry Disease Therapeutic 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Fabry Disease Therapeutic 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Fabry Disease Therapeutic 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Fabry Disease Therapeutic 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Fabry Disease Therapeutic 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Fabry Disease Therapeutic 麻豆原创 Size (2018-2029)
9.2 Latin America Fabry Disease Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Fabry Disease Therapeutic 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Fabry Disease Therapeutic 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Fabry Disease Therapeutic 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Fabry Disease Therapeutic 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Fabry Disease Therapeutic 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Fabry Disease Therapeutic 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amicus therapeutics
11.1.1 Amicus therapeutics Company Detail
11.1.2 Amicus therapeutics Business Overview
11.1.3 Amicus therapeutics Fabry Disease Therapeutic Introduction
11.1.4 Amicus therapeutics Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.1.5 Amicus therapeutics Recent Development
11.2 Takeda
11.2.1 Takeda Company Detail
11.2.2 Takeda Business Overview
11.2.3 Takeda Fabry Disease Therapeutic Introduction
11.2.4 Takeda Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.2.5 Takeda Recent Development
11.3 Genzyme-Sanofi
11.3.1 Genzyme-Sanofi Company Detail
11.3.2 Genzyme-Sanofi Business Overview
11.3.3 Genzyme-Sanofi Fabry Disease Therapeutic Introduction
11.3.4 Genzyme-Sanofi Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.3.5 Genzyme-Sanofi Recent Development
11.4 Protalix
11.4.1 Protalix Company Detail
11.4.2 Protalix Business Overview
11.4.3 Protalix Fabry Disease Therapeutic Introduction
11.4.4 Protalix Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.4.5 Protalix Recent Development
11.5 Sanofi-Aventis LLC
11.5.1 Sanofi-Aventis LLC Company Detail
11.5.2 Sanofi-Aventis LLC Business Overview
11.5.3 Sanofi-Aventis LLC Fabry Disease Therapeutic Introduction
11.5.4 Sanofi-Aventis LLC Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.5.5 Sanofi-Aventis LLC Recent Development
11.6 Novartis Pharmaceuticals
11.6.1 Novartis Pharmaceuticals Company Detail
11.6.2 Novartis Pharmaceuticals Business Overview
11.6.3 Novartis Pharmaceuticals Fabry Disease Therapeutic Introduction
11.6.4 Novartis Pharmaceuticals Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.6.5 Novartis Pharmaceuticals Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Fabry Disease Therapeutic Introduction
11.7.4 Pfizer Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Company Detail
11.8.2 Bristol-Myers Squibb Company Business Overview
11.8.3 Bristol-Myers Squibb Company Fabry Disease Therapeutic Introduction
11.8.4 Bristol-Myers Squibb Company Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.8.5 Bristol-Myers Squibb Company Recent Development
11.9 GlaxoSmithKline plc
11.9.1 GlaxoSmithKline plc Company Detail
11.9.2 GlaxoSmithKline plc Business Overview
11.9.3 GlaxoSmithKline plc Fabry Disease Therapeutic Introduction
11.9.4 GlaxoSmithKline plc Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.9.5 GlaxoSmithKline plc Recent Development
11.10 Amgen Inc.
11.10.1 Amgen Inc. Company Detail
11.10.2 Amgen Inc. Business Overview
11.10.3 Amgen Inc. Fabry Disease Therapeutic Introduction
11.10.4 Amgen Inc. Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.10.5 Amgen Inc. Recent Development
11.11 Teva pharmaceutical Industries Ltd.
11.11.1 Teva pharmaceutical Industries Ltd. Company Detail
11.11.2 Teva pharmaceutical Industries Ltd. Business Overview
11.11.3 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Introduction
11.11.4 Teva pharmaceutical Industries Ltd. Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.11.5 Teva pharmaceutical Industries Ltd. Recent Development
11.12 Merc & Co.
11.12.1 Merc & Co. Company Detail
11.12.2 Merc & Co. Business Overview
11.12.3 Merc & Co. Fabry Disease Therapeutic Introduction
11.12.4 Merc & Co. Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.12.5 Merc & Co. Recent Development
11.13 AbbVie Inc.
11.13.1 AbbVie Inc. Company Detail
11.13.2 AbbVie Inc. Business Overview
11.13.3 AbbVie Inc. Fabry Disease Therapeutic Introduction
11.13.4 AbbVie Inc. Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.13.5 AbbVie Inc. Recent Development
11.14 Takeda Pharmaceutical Co. Ltd.
11.14.1 Takeda Pharmaceutical Co. Ltd. Company Detail
11.14.2 Takeda Pharmaceutical Co. Ltd. Business Overview
11.14.3 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Introduction
11.14.4 Takeda Pharmaceutical Co. Ltd. Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.14.5 Takeda Pharmaceutical Co. Ltd. Recent Development
11.15 Green Cross Corp.
11.15.1 Green Cross Corp. Company Detail
11.15.2 Green Cross Corp. Business Overview
11.15.3 Green Cross Corp. Fabry Disease Therapeutic Introduction
11.15.4 Green Cross Corp. Revenue in Fabry Disease Therapeutic Business (2018-2023)
11.15.5 Green Cross Corp. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Amicus therapeutics
Takeda
Genzyme-Sanofi
Protalix
Sanofi-Aventis LLC
Novartis Pharmaceuticals
Pfizer
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Amgen Inc.
Teva pharmaceutical Industries Ltd.
Merc & Co.
AbbVie Inc.
Takeda Pharmaceutical Co. Ltd.
Green Cross Corp.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.